Dash Acquisitions Inc. Acquires Shares of 4,285 IDEXX Laboratories, Inc. $IDXX

Dash Acquisitions Inc. purchased a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 4,285 shares of the company’s stock, valued at approximately $2,690,000.

A number of other institutional investors have also recently modified their holdings of the business. Empowered Funds LLC grew its stake in shares of IDEXX Laboratories by 6.6% during the 1st quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock worth $646,000 after purchasing an additional 95 shares during the period. Sivia Capital Partners LLC purchased a new stake in IDEXX Laboratories during the second quarter worth about $265,000. Park Avenue Securities LLC grew its position in IDEXX Laboratories by 9.1% during the second quarter. Park Avenue Securities LLC now owns 2,470 shares of the company’s stock worth $1,325,000 after buying an additional 206 shares during the period. Public Employees Retirement System of Ohio increased its holdings in IDEXX Laboratories by 3.9% in the second quarter. Public Employees Retirement System of Ohio now owns 27,716 shares of the company’s stock valued at $14,865,000 after buying an additional 1,041 shares in the last quarter. Finally, Mather Group LLC. increased its holdings in IDEXX Laboratories by 92.4% in the second quarter. Mather Group LLC. now owns 1,462 shares of the company’s stock valued at $784,000 after buying an additional 702 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP Nimrata Hunt sold 9,425 shares of the business’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the transaction, the executive vice president directly owned 21,149 shares of the company’s stock, valued at approximately $14,874,937.66. The trade was a 30.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Trading Up 0.4%

Shares of IDXX opened at $693.85 on Friday. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $769.98. The company has a market capitalization of $55.40 billion, a PE ratio of 55.02, a price-to-earnings-growth ratio of 3.70 and a beta of 1.67. The stock has a fifty day moving average of $705.83 and a two-hundred day moving average of $654.72. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.87 and a current ratio of 1.18.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.08. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The business had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter last year, the firm earned $2.80 earnings per share. The business’s revenue was up 13.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. As a group, analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on IDXX. JPMorgan Chase & Co. boosted their price target on IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. BTIG Research lifted their price objective on IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Wall Street Zen downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 17th. Morgan Stanley raised their target price on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Finally, Weiss Ratings upgraded IDEXX Laboratories from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, January 12th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $763.50.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.